SCHEMBL9102415

SCHEMBL9102415

COC(=O)c1ccc2c(Cl)cnc(O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 2/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
XDH P47989 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LCK P06239 1/20 0.46
MAPK1 P28482 2/20 0.44
KDM4E B2RXH2 2/20 0.42
ALOX15 P16050 2/20 0.42
HTT P42858 2/20 0.42
TP53 P04637 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907434 0.85 CSNK2A1 (0.47) CSNK2A1CA12CA1CA2CA7
SCHEMBL9106546 0.82 CA12 (0.46) CSNK2A1CA12CA1CA2CA7
SCHEMBL9102332 0.82 CA12 (0.46) CSNK2A1CA12CA1CA2CA7
SCHEMBL9107870 0.82 CA12 (0.46) CSNK2A1CA12CA1CA2CA7
SCHEMBL17436940 0.81 CSNK2A1 (0.46) CSNK2A1CA12CA1CA2CA7
SCHEMBL9907706 0.80 MAP2K4 (0.45) CSNK2A1MAPK1KDM4ETP53MEN1
SCHEMBL9907650 0.79 NOTUM (0.52) CSNK2A1CA12CA1CA2CA7
SCHEMBL16151833 0.79 CA12 (0.43) CSNK2A1CA12CA1CA2CA7
SCHEMBL9907661 0.79 HTR5A (0.52) CSNK2A1ALDH1A1KDM4EHTTTP53
SCHEMBL9107174 0.79 HTR5A (0.43) CSNK2A1CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E CSNK2A1 4309/4885CA12 4819/4885CA1 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.